Asset profile
DA-302168S
Small molecule
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-07-09.
NCT06953063: The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 34 direct rivals (same mechanism and indication), 16 same-class, 60 same-indication; 10 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| DA-302168S: this drug | Phase 3 | Small molecule | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| ASC30 | Phase 3 | Small molecule | GLP-1 receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CX11 | Phase 3 | Small molecule | GLP-1 receptor | ||
| Ecnoglutide | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Enicepatide | Phase 3 | Peptide | GLP-1 receptor, GLP-1/GIP receptor (dual) | ||
| GZR18 | Phase 3 | Peptide | GLP-1 receptor | ||
| HDM1002 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor | ||
| MDR-001 | Phase 3 | Small molecule | GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
28 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.